Treatment of primary pulmonary hypertension -- the next generation.
Newman
John H
JH
D000959:Antihypertensive Agents / Q000627:therapeutic use*; D052006:Bone Morphogenetic Protein Receptors, Type II; D000077300:Bosentan; D065128:Endothelin Receptor Antagonists; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000235:genetics; D009154:Mutation; D017346:Protein Serine-Threonine Kinases / Q000235:genetics; D018125:Receptors, Transforming Growth Factor beta / Q000235:genetics; D013449:Sulfonamides / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000627:therapeutic use
D000959:Antihypertensive Agents; D065128:Endothelin Receptor Antagonists; D018125:Receptors, Transforming Growth Factor beta; D013449:Sulfonamides; D014665:Vasodilator Agents; D017346:Protein Serine-Threonine Kinases; C498218:BMPR2 protein, human; D052006:Bone Morphogenetic Protein Receptors, Type II; D000077300:Bosentan